Ancora Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Ancora Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3	Closed	–	–	1972
2021 Q1	$0	Buy	+3	New	+$395	﹤0.01%	1782

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ancora Advisors's INO Position: Q2 2021 in Review

Ancora Advisors sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 3 shares.

Ancora Advisors first reported a position in INO in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

Ancora Advisors reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Ancora Advisors sold 3 Inovio Pharmaceuticals shares in Q2 2021.
Ancora Advisors first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Ancora Advisors's Inovio Pharmaceuticals position peaked at $0 in Q1 2021.
211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on Ancora Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.